A study from Mass General Brigham and Harvard Medical School raises questions about a new class of weight loss drugs — and ...

Experts say that semaglutide and tirzepatide can help patients with heart failure lose weight, but limited NHS access is ...

Since the FDA said shortages of Wegovy and Zepbound are over, compounding pharmacies are supposed to stop making copies of the drugs. But some of those business are trying to find ways to continue.

It’s the hot-shot fix that took Hollywood — and now high school — by storm. Ozempic and other so-called “miracle” weight-loss ...

Like in the STRIDE study of PAD, GLP-1s improved outcomes, but more work is needed to clarify who may benefit most.

Regeneron signed a deal with China-based Hansoh Pharma for HS-20094, an investigational, late-stage anti-obesity asset. Per ...

Metsera is advancing promising obesity treatments with amylin and GLP-1 analogs, eyeing competitive efficacy and buyout ...

Bisexual, gay and lesbian medical students are more likely to leave school before graduation, a new study says. These ...

Real-world results for blockbuster weight-loss meds like Ozempic, Wegovy and Zepbound aren't as impressive as those promised ...

People who take weight-loss drugs hoping to achieve the impressive results observed in large clinical trials may need to ...

Key Takeaways Real-world results with weight-loss drugs aren’t as impressive as those in clinical trialsClinic patients ...

A Cleveland Clinic study shows that semaglutide and tirzepatide—injectable GLP-1 drugs for obesity—produce smaller weight ...